LLY News and Press, Eli Lilly and Company From 12/07/23

2023-12-07 05:50:00 ET Many investors have flocked to big pharma stocks throughout the years. And doing so has paid off handsomely with several of those stocks. AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) stand out as two of the biggest pharma stocks around. Both have ...

2023-12-06 11:38:31 ET More on S&P 500 Index: The November Labor Report - Bad News Will Be Bad News For Stocks Markets Catch Collective Breath The December Fed Meeting: What To Expect And How To Trade It Buy-rated laggards with out-of-consensus estimates ...

2023-12-06 11:15:12 ET More on SPDR S&P 500 ETF Trust: Only Thing That Matters Is Price; Nasdaq Has Further To Go - Cestrian Capital Research The December Fed Meeting: What To Expect And How To Trade It 2024 Analyst Outlook: Leo Nelissen On Staying Defensive In A...

2023-12-06 05:38:29 ET Summary Positive results were achieved from the 48-week phase 2 MOMENTUM study using pemvidutide for the treatment of patients with obesity. The highest dose of 2.4 mg of pemvidutide achieved 15.6% weight loss for obese patients. Altimmune has two other ...

2023-12-05 09:54:36 ET Goldman Sachs published its Hedge Fund Trend Monitor and Mutual Fundamentals reports, which analyzed $5 trillion of equity positions at the start of 4Q 2023. Within the Mutual Fundamentals report the investment bank listed the stocks that it was most underweight. ...

Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium PR Newswire Results from MONARCH 3 show a numerical improvement in ...

2023-12-05 07:58:20 ET Eli Lilly ( NYSE: LLY ) announced on Tuesday the U.S. availability of its weight loss drug Zepbound (tirzepatide), a GIP/GLP-1 duo agonist. Last month, the U.S. Food and Drug Administration approved the Zepbound for chronic weight management, after adu...

Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity PR Newswire Express Scripts to add Zepbound to National Preferred Formulary INDIANAPOLIS , Dec. 5, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) tod...

2023-12-05 07:30:00 ET The U.S. Food and Drug Administration has granted Bristol Myers Squibb ( NYSE: BMY ) a priority review for its supplemental biologics license application of a combination therapy for patients with untreated, unresectable or metastatic urothelial carcinoma....

2023-12-05 05:53:10 ET Vanda Pharma ( NASDAQ: VNDA ) shares jumped 19% premarket on Tuesday as the FDA accepted the new drug application (NDA) for tradipitant, an experimental drug for the treatment of gastroparesis. Tradipitant is a neurokinin 1 antagonist licensed by V...